Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research

Abstract Once considered an incurable disease with a poor prognosis (median survival, 3–6 years), chronic myeloid leukemia (CML) is now managed with a diverse clinical armamentarium that includes BCR::ABL1 tyrosine kinase inhibitors (TKIs), which have largely normalized life expectancy in most patients in the chronic phase of the disease (CML‐CP). Clinical challenges remain, including ABL1 mutation–driven treatment resistance (under the selection pressures exerted by TKIs), as well as treatment intolerance, which can involve potentially serious arterial occlusive events. Olverembatinib is a third‐generation TKI approved in China for TKI‐resistant CML‐CP and accelerated‐phase CML with the T135I mutation, as well as for CML‐CP resistant to or intolerant of first‐ and/or second‐generation TKIs. Olverembatinib exhibits a broad coverage of ABL1 mutants, including the gatekeeper T315I variant and compound mutations. In preclinical models, olverembatinib inhibited multiple downstream protein kinases, which has potentially opened avenues for future management of other malignancies, including acute myeloid and lymphoid leukemias, gastrointestinal tumors, and others. The pharmacokinetic profile of olverembatinib is compatible with alternate‐day dosing. In clinical trials, olverembatinib exerted potent antileukemic effects in heavily pretreated patients with CML, including those with ponatinib or asciminib resistance or intolerance, and was well tolerated. Future studies include the phase 3 registrational POLARIS‐1 (NCT06051409; in patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia), POLARIS‐2 (NCT06423911; in patients with CML with or without the T315I mutation), and POLARIS‐3 (NCT06640361; in patients with succinate dehydrogenase–deficient gastrointestinal stromal tumors) clinical trials.